A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Overview of attention for article published in Cancers, December 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 10 news outlets

twitter: 2 X users

Readers on

mendeley: 29 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,554 followers.

New article: A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. https://t.co/IWWa70zmOM #MDS #mdssm #hematology

https://t.co/cD0oHJC18z

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.